Progress tracking: Offer regular body composition assessments, not just weight, to help members see their progress beyond the scale
But while access to high-quality eating disorder treatment remains incredibly limited, especially for those experiencing BED or atypical presentations, it is sadly inevitable that people will find solace in these medications
targets the appetite centres of the brain, reducing hunger cravings
The most common denial reasons in 2026 are insufficient BMI documentation, missing comorbidity ICD-10 codes, lack of lifestyle intervention notes, and step therapy not completed
Ceramide and Cerebroside from the stem bark of Ficus mucuso (Moraceae)
GLP-1 RAs under development for NASH Semaglutide Semaglutide showed a significant dose-dependent NASH resolution without worsening of fibrosis in a phase 2 randomized controlled trial (RCT) involving patients with NASH and stage 13 fibrosis